Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach

Abstract

Objectives:

Despite being approved and effective, steroids, and especially dexamethasone intravitreal implants, still have a poorly-defined role in management of diabetic macular edema. In order to overcome some of the limitations in current recommendations, a group of experts met to define consensus on some of the most controversial issues on the use of dexamethasone intravitreal implants in daily management of diabetic macular edema.

Methods:

A Delphi-based approach was utilized to develop clinically relevant statements applicable to routine treatment settings. A Steering Committee composed of four experts formulated 30 relevant statements, which were voted upon by a panel of 40 ophthalmologists/retinal specialists from across Italy.

Results:

Dexamethasone intravitreal implants were considered to be a valid first-line alternative to treatment with an anti–vascular endothelial growth factor agent and should be the first choice in pseudophakic and vitrectomized patients. A Pro Re Nata regimen was felt to be appropriate for retreatment with dexamethasone intravitreal implants while a 6-month waiting period was not considered suitable. Among steroid treatments, dexamethasone intravitreal implants were considered to have the best ocular tolerability. In patients with persistent macular edema after the loading-phase treatment with an anti–vascular endothelial growth factor, consensus was reached that clinicians should consider switching therapy to dexamethasone intravitreal implants. Moreover, dexamethasone intravitreal implants can reduce the treatment burden for individuals who are not able to cope with the more intensive treatment regimen required by anti–vascular endothelial growth factor therapy.

Conclusions:

While further studies are needed, this survey provides some key recommendations for clinicians treating diabetic macular edema that may be useful when choosing dexamethasone intravitreal implants in daily practice.

Keywords

Diabetic macular edema intravitreal dexamethasone implant Delphi consensus treatment anti–vascular endothelial growth factor

Get full access to this article

View all access options for this article.

References

Klein

BE.

Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14(4): 179–183.

Zhang

Liu

Al-Shabrawey

et al . Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011; 2(2): 96–103.

Solomon

Chew

Duh

et al . Diabetic retinopathy: a position statement by the American diabetes association. Diabetes Care 2017; 40(3): 412–418.

Sun

Radwan

Soliman

et al . Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes 2015; 64(7): 2560–2570.

Boyer

Hopkins

Sorof

et al . Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013; 4(6): 151–169.

Ford

Lois

Royle

et al . Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open 2013; 3(3): e002269.

Dugel

Bandello

Loewenstein

Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 2015; 9: 1321–1335.

American Academy of Ophthalmology. Preferred practice patterns, https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2017 (accessed 27 June 2017).

International Council for Ophthalmology. ICO Guidelines for Diabetic Eye Care: http://www.icoph.org/downloads/ICOGuidelinesforDiabeticEyeCare.pdf (accessed 27 June 2017).

10.

Schmidt-Erfurth

Garcia-Arumi

Bandello

et al . Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica 2017; 237(4): 185–222.

11.

Hussain

Ciulla

TA.

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther 2016; 16(3): 365–374.

12.

Loblaw

Prestrud

Somerfield

et al . American society of clinical oncology clinical practice guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30(25): 3136–3140.

13.

Roy

Kern

Song

et al . Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy. Am J Pathol 2017; 187(1): 9–19.

14.

Wan

Sun

et al . Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Biomed Pharmacother 2015; 74: 145–147.

15.

Romero-Aroca

Baget-Bernaldiz

Pareja-Rios

et al . Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016; 2016: 2156273.

16.

Ascaso

Huerva

Grzybowski

The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm 2014; 2014: 432685.

17.

Campochiaro

Hafiz

Mir

et al . Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol 2016; 168: 13–23.

18.

Sohn

Han

Kim

et al . Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152(4): 686–694.

19.

Vujosevic

Torresin

Bini

et al . Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol 2017: 95(5): 464–471.

20.

Boyer

Yoon

Belfort

et al . Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121(10): 1904–1914.

21.

Callanan

Loewenstein

Patel

et al . A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2017; 255(3): 463–473.

22.

Gillies

Lim

Campain

et al . A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121(12): 2473–2481.

23.

Boyer

Faber

Gupta

et al . Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31(5): 915–923.

24.

Medeiros

Alkabes

Navarro

et al . Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther 2014; 30(9): 709–716.

25.

Nguyen-Khoa

Goehring

Werther

et al . Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol 2012; 12: 11.

26.

Nguyen

Brown

Marcus

et al . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119(4): 789–801.

27.

Korobelnik

Schmidt-Erfurth

et al . Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121(11): 2247–2254.

28.

Mitchell

Bandello

Schmidt-Erfurth

et al . The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118(4): 615–625.

29.

Wells

Glassman

Ayala

et al . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123(6): 1351–1359.

30.

Panozzo

Gusson

Panozzo

et al . Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment. Eur J Ophthalmol 2015; 25(4): 347–351.

31.

Malcles

Dot

Voirin

et al . Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina 2017; 37(4): 753–760.

32.

Sarao

Veritti

Furino

et al . Dexamethasone implant with fixed or individualized regimen in the treatment of diabetic macular oedema: six-month outcomes of the UDBASA study. Acta Ophthalmol 2017; 95(4): e255–e260.

33.

Fox

Golden

Anderson

et al . Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American heart association and the American diabetes association. Diabetes Care 2015; 38(9): 1777–1803.

34.

Maturi

Pollack

et al . Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina 2016; 36(6): 1143–1152.

35.

Gonzalez

Campbell

Holekamp

et al . Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 2016; 172: 72–79.

36.

Campochiaro

Brown

Pearson

et al . Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119(10): 2125–2132.

37.

Diabetic Retinopathy Clinical Research Network, Elman

Aiello

et al . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6): 1064–1077.e35.

38.

Bressler

Qin

Melia

et al . Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013; 131(8): 1033–1040.

39.

Lim

Mathur

et al . Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol 2015; 9: 1715–1718.

40.

Rahimy

Shahlaee

Khan

et al . Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016; 164: 118–127.e2.

41.

Augustin

Kuppermann

Lanzetta

et al . Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015; 15: 150.

42.

Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross

Glassman

et al . Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015; 314(20): 2137–2146.

43.

Khan

Kuriakose

Khan

et al . Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina 2017; 48(2): 160–166.

44.

Bandello

Polito

Pognuz

et al . Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006; 124(5): 643–650.

45.

Iacono

Parodi

Scaramuzzi

et al . Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol 2017; 101(6): 791–795.

46.

Sivaprasad

Prevost

Vasconcelos

et al . Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 2017; 389(10085): 2193–2203.

47.

Chen

Looman

Laouri

et al . Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010; 26(7): 1587–1597.

48.

Brown

Nguyen

Marcus

et al . Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120(10): 2013–2022.

49.

Nguyen

Boyer

et al . One-year outcomes of the Da Vinci study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012; 119(8): 1658–1665.

50.

Sivaprasad

Oyetunde

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol 2016; 10: 939–946.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB